CN103417952B - Oral medicine composition for treating rheumatoid arthritis - Google Patents
Oral medicine composition for treating rheumatoid arthritis Download PDFInfo
- Publication number
- CN103417952B CN103417952B CN201310399592.4A CN201310399592A CN103417952B CN 103417952 B CN103417952 B CN 103417952B CN 201310399592 A CN201310399592 A CN 201310399592A CN 103417952 B CN103417952 B CN 103417952B
- Authority
- CN
- China
- Prior art keywords
- parts
- rheumatoid arthritis
- combination
- oral medication
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010039073 rheumatoid arthritis Diseases 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title abstract description 19
- 239000000463 material Substances 0.000 claims abstract description 8
- 229940126701 oral medication Drugs 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 14
- 239000002994 raw material Substances 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 241000304531 Allium macrostemon Species 0.000 abstract description 2
- 240000001341 Reynoutria japonica Species 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract description 2
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 2
- 235000008397 ginger Nutrition 0.000 abstract description 2
- 244000237330 gutta percha tree Species 0.000 abstract description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241000124033 Salix Species 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 abstract 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 abstract 1
- 235000005822 corn Nutrition 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 108010074051 C-Reactive Protein Proteins 0.000 description 6
- 102100032752 C-reactive protein Human genes 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 3
- 240000008384 Capsicum annuum var. annuum Species 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 241001079064 Zanthoxylum schinifolium Species 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000008822 Ankylosis Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241001279228 Campylotropis hirtella Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 241000208293 Capsicum Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000002567 Capsicum annuum Nutrition 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000208686 Eucommiaceae Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 241000612122 Myrsine Species 0.000 description 1
- OSKIPPQETUTOMW-YHLOVPAPSA-N N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-Acetamido-5-[(2R,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3S,4S,5R,6R)-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxy-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 OSKIPPQETUTOMW-YHLOVPAPSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 244000020191 Salix babylonica Species 0.000 description 1
- 235000002493 Salix babylonica Nutrition 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000032846 Zanthoxylum bungeanum Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 210000001306 articular ligament Anatomy 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000037306 mature skin Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an oral medicine composition for treating the rheumatoid arthritis. The oral medicine composition for treating the rheumatoid arthritis comprises the following traditional Chinese medicinal materials which are 20 to 30 parts of dried ginger, 20 to 30 parts of willow branches, 10 to 16 parts of pericarpium zanthoxyli, 10 to 16 parts of eucommia ulmoides, 15 to 22 parts of allium macrostemon, 15 to 22 parts of polygonum cuspidatum, 15 to 22 parts of corn stigmas and 15 to 22 parts of dandelions. The oral medicine composition for treating the rheumatoid arthritis has the advantages that the cellular immune response of a rheumatoid arthritis patient can be regulated, the rheumatoid arthritis is fundamentally treated, clinical symptoms can be relieved and eliminated rapidly, the curative effect is continuous and stable, and the composition has a certain relapse resistance function.
Description
Technical field
The invention belongs to technical field of Chinese medicine, particularly a kind of combination of oral medication for the treatment of rheumatoid arthritis.
Background technology
Rheumatoid arthritis is a kind of based on the systemic autoimmune disease of the non-infectious inflammation of joint and periarticular tissue.Based on synovium of joint pathological changes, the later stage can cause ankylosis, deformity and severe dysfunction.
Rheumatoid arthritis for main clinical manifestation, belongs to autoimmune inflammatory disease with pathological changes outside chronic, symmetry, many synovial jointss inflammation and joint.This disease is apt to occur in the Minor articulus such as hands, wrist, foot, and recurrent exerbation, is symmetric.Having joint red and swollen heat pain and dysfunction in early days, can there is stiff deformity in various degree in advanced joint, and with the atrophy of bone and bones flesh, very easily disables.From the angle of pathological change, rheumatoid arthritis is that one mainly involves synovium of joint (later can feed through to articular cartilage, osseous tissue, articular ligament and flesh key), is secondly the popularity diseases associated with inflammation of the connective tissues such as serous coat, the heart, lung and eye.The systemic manifestation of rheumatoid arthritis, except arthropathy, also has heating, fatigue and weak, pericarditis, subcutaneous nodule, pleuritis, arteritis, peripheral neuropathy etc.
Summary of the invention
The object of the present invention is to provide a kind of combination of oral medication for the treatment of rheumatoid arthritis.This combination of oral medication, as secret prescription handed down in the family from generation to generation, has treating both the principal and secondary aspects of a disease, good effect, advantage that recurrence rate after healing is low, determines that it is a kind of specific medicament for the treatment of rheumatoid arthritis after many decades clinical practice.
The object of the present invention is achieved like this:
A kind of combination of oral medication for the treatment of rheumatoid arthritis, be made up of active component and pharmaceutic adjuvant, described active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Rhizoma Zingiberis 20-30 part, Ramulus Salicis Babylonicae 20-30 part, Fructus Zanthoxyli 10-16 part, Cortex Eucommiae 10-16 part, Bulbus Allii Macrostemonis 15-22 part, Rhizoma Polygoni Cuspidati 15-22 part, Stigma Maydis 15-22 part and Herba Taraxaci 15-22 part.
Preferably, the combination of oral medication of above-mentioned treatment rheumatoid arthritis, wherein said active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Rhizoma Zingiberis 23-26 part, Ramulus Salicis Babylonicae 23-26 part, Fructus Zanthoxyli 12-15 part, Cortex Eucommiae 12-15 part, Bulbus Allii Macrostemonis 18-20 part, Rhizoma Polygoni Cuspidati 18-20 part, Stigma Maydis 18-20 part and Herba Taraxaci 18-20 part.
In an embodiment most preferably of the present invention, the active component of the combination of oral medication of above-mentioned treatment rheumatoid arthritis is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Rhizoma Zingiberis 25 parts, Ramulus Salicis Babylonicae 25 parts, Fructus Zanthoxyli 13 parts, the Cortex Eucommiae 13 parts, Bulbus Allii Macrostemonis 18 parts, Rhizoma Polygoni Cuspidati 18 parts, Stigma Maydis 20 parts and Herba Taraxaci 20 parts.
Further preferably, the combination of oral medication of above-mentioned treatment rheumatoid arthritis, wherein said pharmaceutic adjuvant comprises diluent and lubricant, and described diluent is selected from following one or more: starch, dextrin, microcrystalline Cellulose, lactose, sucrose; Described lubricant is selected from magnesium stearate and/or Pulvis Talci.
Again further preferably, the combination of oral medication of above-mentioned treatment rheumatoid arthritis, it is solid orally ingestible; Described solid orally ingestible is preferably capsule, tablet, granule.
It should be noted that, the Chinese crude drug selected by the present invention has following function and cures mainly and originate:
Rhizoma Zingiberis: warming spleen and stomach for dispelling cold, recuperating depleted YANG is promoted blood circulation, dampness expectorant, warming the lung to resolve fluid-retention.Cure mainly coldness and pain in the epigastrium; Vomiting; Have loose bowels, YANG-depletion is fainted inverse; Cold fluid-retention is breathed with cough; Arthralgia due to cold-dampnes.Select the dry rhizome of zingiber Zingiber officinale Rosc..
Ramulus Salicis Babylonicae: dispel the wind, diuresis, pain relieving, detumescence.Dispelling the wind and dampness pathogens arthralgia pain, gonorrhea, nebulousurine, urinary obstruction, infectious hepatitis, swelling due to wind, furuncle, erysipelas, dental caries, swelling of the gum.Select the dry branch of Salicaceous Plants Salix babylonica L..
Fructus Zanthoxyli: warming middle-JIAO to relieve pain, killing parasites for relieving itching.For coldness and pain in the epigastrium, vomiting is had loose bowels, abdominal pain due to worm stagnation, ascariasis; External treatment eczema pruritus.The dry mature skin (Pericarpium Zanthoxyli) of rutaceae Capsicum annuum L. (fragrant green pepper, Zanthoxylum schinifolium, Pericarpium Zanthoxyli, Canis familiaris L. green pepper) Zanthoxylum schinifolium Sieb.et Zucc. or Pericarpium Zanthoxyli (another name for Sichuan Province green pepper, Fructus Zanthoxyli, Capsicum tetragonum, pericarpium zanthoxyli bungeani, Radix Campylotropis Hirtella (Herba Myrsines Africanae)) Zanthoxylum bungeanum Maxim. is selected to be used as medicine.
The Cortex Eucommiae: invigorating the liver and kidney, bone and muscle strengthening, antiabortive.Control spinal column ache, foot and knee flaccidity, dribbling urination, uncontrolled urination is itched, vaginal bleeding during pregnancy for falling, frequent fetal movement, hypertension.Select the dry bark of the Eucommiaceae plant Cortex Eucommiae (Eucommia ulmoides Oliver).
Bulbus Allii Macrostemonis: the dry bulb selecting liliaceous plant Allium macrostemon Allium macrostemon Bge., summer, Qiu Erji excavate, and clean, removing fibrous root, steam thoroughly or put in boiling water and scald thoroughly, dry.There is activating YANG and eliminating stagnation, effect of circulation of qi promoting intestinal stasis relieving.For thoracic obstruction pain, phlegm retention cough with asthma is heavy after letting out dysentery.
Rhizoma Polygoni Cuspidati: heat-clearing and toxic substances removing, promoting the function of the gallbladder to alleviate jaundice, expelling wind and removing dampness, dissipating blood stasis analgesic therapy, relieving cough and resolving phlegm.For arthralgia, jaundice due to damp-heat, amenorrhea ， WEIJIA, cough with copious phlegm, burn due to hot liquid or fire, injury from falling down, carbuncle sore tumefacting virus.Select Polygonaceae Polygonaceae plant polygonum cuspidatum Polygonum cuspidatum Sieb. et Zucc., dry rhizome and root.
Stigma Maydis: diuresis, expels the heat-evil, suppressing the hyperactive liver, function of gallbladder promoting.Control oedema due to nephritis, beriberi, icterohepatitis, hypertension, cholecystitis, cholelithiasis, diabetes, hematemesis and epistaxis, nasal sinusitis, acute mastitis.The present invention selects style and the stigma of grass Semen Maydis ZeamaysL..
Herba Taraxaci: there is heat-clearing and toxic substances removing, dispersing swelling and dissipating binds, effect of inducing diuresis for treating stranguria syndrome.For furuncle swelling toxin, acute mastitis, scrofula, conjunctival congestion, pharyngalgia, lung abscess, acute appendicitis, jaundice due to damp-heat, the puckery pain of pyretic stranguria.Be selected from the herb of dry Herba Taraxaci.
By the preparation method that above-mentioned each Chinese medicinal components is prepared into compound preparation of the present invention be: take Rhizoma Zingiberis 20-30 part of recipe quantity, Ramulus Salicis Babylonicae 20-30 part, Fructus Zanthoxyli 10-16 part, Cortex Eucommiae 10-16 part, Bulbus Allii Macrostemonis 15-22 part, Rhizoma Polygoni Cuspidati 15-22 part, Stigma Maydis 15-22 part and Herba Taraxaci 15-22 part, add the water of 10-12 times amount, soak 12h-16h, then decoct three times, first time decocts 1.5-2h, leaches medicinal liquid stand-by; Second time adds the water of 8-10 times amount, decocts 1-1.5h, leaches medicinal liquid stand-by; Add the water of 6-8 times amount for the third time, decoct 0.8-1h, leach medicinal liquid stand-by; Merge three decocting liquids, filter, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1.25-1.35, low-temperature bake 6-8h, and get dry extract powder; By dried cream powder: dextrin is that the weight ratio of 1:0.5-1.5 adds adjuvant, common process is granulated, and is sub-packed in capsule after granulate, uses
60co irradiation bomb irradiation sterilization, obtains Chinese medicine preparation of the present invention.
Inventor through studying for many years, treat and observing, obtains combination of oral medication of the present invention clinically.This medicine can reconcile the cell immune response of rheumatoid arthritis patients, fundamentally treats rheumatoid arthritis patients, has and alleviates and eliminate the feature that clinical symptoms is fast, curative effect is continual and steady, and have certain anti-recurrence effect.
Detailed description of the invention
Form is described in further detail foregoing of the present invention again by the following examples, but this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following embodiment, all technology realized based on foregoing of the present invention all belong to scope of the present invention.
The preparation of embodiment 1 Chinese medicine capsules
Crude drug prescription: Rhizoma Zingiberis 2.5 kilograms, Ramulus Salicis Babylonicae 2.5 kilograms, Fructus Zanthoxyli 1.3 kilograms, the Cortex Eucommiae 1.3 kilograms, Bulbus Allii Macrostemonis 1.8 kilograms, Rhizoma Polygoni Cuspidati 1.8 kilograms, Stigma Maydis 2 kilograms, Herba Taraxaci 2 kilograms.
Preparation technology: the above-mentioned traditional Chinese medicinal material raw materials taking recipe quantity, pulverizes, and mixing, adds the water of 12 times amount, soaks 14h, then decocts three times, and first time decocts 1.5h, leaches medicinal liquid stand-by; Second time adds the water of 9 times amount, decocts 1.2h, leaches medicinal liquid stand-by; Add the water of 8 times amount for the third time, decoct 0.8h, leach medicinal liquid stand-by; Merge three decocting liquids, filter, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1.3, low-temperature bake 7h, and get dry extract powder; By dried cream powder: dextrin is that the weight ratio of 1:1.2 adds adjuvant, common process is granulated, and is sub-packed in capsule after granulate, and every capsules, by the crude drug amount powder charge of 30 grams, is used
60co irradiation bomb irradiation sterilization, obtains capsule preparations.
The preparation of embodiment 2 Chinese medicine capsules
Crude drug prescription: Rhizoma Zingiberis 2.1 kilograms, Ramulus Salicis Babylonicae 2.8 kilograms, Fructus Zanthoxyli 1.6 kilograms, the Cortex Eucommiae 1.6 kilograms, Bulbus Allii Macrostemonis 1.6 kilograms, Rhizoma Polygoni Cuspidati 2.2 kilograms, Stigma Maydis 2.2 kilograms, Herba Taraxaci 1.5 kilograms.
Preparation technology: the above-mentioned traditional Chinese medicinal material raw materials taking recipe quantity, pulverizes, and mixing, adds the water of 11 times amount, soaks 16h, then decocts three times, and first time decocts 2h, leaches medicinal liquid stand-by; Second time adds the water of 9 times amount, decocts 1.5h, leaches medicinal liquid stand-by; Add the water of 8 times amount for the third time, decoct 1h, leach medicinal liquid stand-by; Merge three decocting liquids, filter, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1.3, low-temperature bake 8h, and get dry extract powder; By dried cream powder: dextrin is that the weight ratio of 1:1 adds adjuvant, common process is granulated, and is sub-packed in capsule after granulate, uses
60co irradiation bomb irradiation sterilization, obtains capsule preparations.
The preparation of embodiment 3 Chinese medicine capsules
Crude drug prescription: Rhizoma Zingiberis 3 kilograms, Ramulus Salicis Babylonicae 2 kilograms, Fructus Zanthoxyli 1 kilogram, the Cortex Eucommiae 1 kilogram, Bulbus Allii Macrostemonis 2.2 kilograms, Rhizoma Polygoni Cuspidati 1.5 kilograms, Stigma Maydis 1.5 kilograms, Herba Taraxaci 2.2 kilograms.
Preparation technology: the above-mentioned traditional Chinese medicinal material raw materials taking recipe quantity, pulverizes, and mixing, adds the water of 12 times amount, soaks 15h, then decocts three times, and first time decocts 1.5h, leaches medicinal liquid stand-by; Second time adds the water of 8 times amount, decocts 1h, leaches medicinal liquid stand-by; Add the water of 8 times amount for the third time, decoct 0.8h, leach medicinal liquid stand-by; Merge three decocting liquids, filter, collect filtrate; Filtrate is concentrated into the thick paste that relative density is 1.3, low-temperature bake 7h, and get dry extract powder; By dried cream powder: dextrin is that the weight ratio of 1:1.2 adds adjuvant, common process is granulated, and is sub-packed in capsule after granulate, uses
60co irradiation bomb irradiation sterilization, obtains capsule preparations.
The experimental study of embodiment 4 Progress on Traditional Chinese Medicine Curing Rheumatoid Arthritis
Patient with rheumatoid arthritis 27 example, wherein man 8 example, female 19 example; Age average (50.2 ± 4.5) year, the course of disease average (4.2 ± 0.7) year.Capsule prepared by the oral embodiment of the present invention 1 of all patients, sooner or later respectively taking 3,6 weeks is 1 course for the treatment of, treats 2 courses for the treatment of continuously.Period in a medicine withdraws other Chinese and western drugses.
Observation index: (1) ordinary circumstance: tender joint number, pain time and morning stiff time etc.(2) physico-chemical examination: 1. erythrocyte sedimentation rate.2. rheumatoid factor.3. c reactive protein.4. immunoglobulin.
1, general curative effect analysis:
Curative effect determinate standard: the standard of the whole nation, Kunming in 1988 rheumatism academic conference revision.After two course of therapy terminate, in 27 routine patients, clinical remission 5 example, effective 14 examples, take a turn for the better 7 examples, and invalid 1 example, its clinical remission is 18.5%, and obvious effective rate is 70.4%, and total effective rate reaches 96.3%.
2, cardinal symptom relative analysis before and after treatment:
After treatment by Chinese herbs of the present invention, the cardinal symptom of patient obviously reduces, and comparing before and after treatment has obvious difference.Drawn by 27 routine symptom variation, prescription treatment of the present invention 4 ~ 6 Zhou Houjun have alleviation in various degree, and in 8 ~ 12 weeks, patient's cardinal symptom disappears substantially.The results are shown in Table 1.
Cardinal symptom relative analysis (example) before and after table 1 patient treatment
3, the erythrocyte sedimentation rate (ESR) before and after patient treatment, rheumatoid factor (RF), the comparative analysis of c reactive protein (CRP) situation of change:
Have 24 routine ESR to speed before treatment, after treatment, 16 examples transfer to normally, turn normal rate and reach 66.7%; Have 15 routine RF positive before treatment, after treatment, 8 examples transfer feminine gender to, and turning normal rate is have 27 examples for positive before 53.3%, CRP treatment, and have 26 examples to transfer feminine gender to after treatment, turning normal rate is 96.3%.The results are shown in Table 2.
Table 2 treats erythrocyte sedimentation rate, rheumatoid factor, the c reactive protein situation of change (example) of front and back
4, the immunoglobulin comparative analysis before and after patient treatment:
Treatment after IgA, IgG reduce by 42.90% and 38.49% respectively, with treatment before comparing difference have statistical significance (
p< O.01).The results are shown in Table 3.
Table 3 treats erythrocyte sedimentation rate, rheumatoid factor, the c reactive protein situation of change (example) of front and back
Compare with before treatment,
* p< 0.05; Compare with matched group,
* p< 0.01.
Claims (4)
1. treat the combination of oral medication of rheumatoid arthritis for one kind, it is characterized in that: be made up of active component and pharmaceutic adjuvant, by weight, described active component is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Rhizoma Zingiberis 25 parts, Ramulus Salicis Babylonicae 25 parts, Fructus Zanthoxyli 13 parts, the Cortex Eucommiae 13 parts, Bulbus Allii Macrostemonis 18 parts, Rhizoma Polygoni Cuspidati 18 parts, Stigma Maydis 20 parts and Herba Taraxaci 20 parts.
2. treat the combination of oral medication of rheumatoid arthritis according to claim 1, it is characterized in that: described pharmaceutic adjuvant comprises diluent and lubricant, described diluent is selected from following one or more: starch, dextrin, microcrystalline Cellulose, lactose, sucrose; Described lubricant is selected from magnesium stearate and/or Pulvis Talci.
3. treat the combination of oral medication of rheumatoid arthritis according to claim 1, it is characterized in that: described combination of oral medication is solid orally ingestible.
4. treat the combination of oral medication of rheumatoid arthritis according to claim 3, it is characterized in that: described solid orally ingestible is capsule, tablet or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310399592.4A CN103417952B (en) | 2013-09-06 | 2013-09-06 | Oral medicine composition for treating rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310399592.4A CN103417952B (en) | 2013-09-06 | 2013-09-06 | Oral medicine composition for treating rheumatoid arthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103417952A CN103417952A (en) | 2013-12-04 |
| CN103417952B true CN103417952B (en) | 2015-06-24 |
Family
ID=49643692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310399592.4A Active CN103417952B (en) | 2013-09-06 | 2013-09-06 | Oral medicine composition for treating rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103417952B (en) |
-
2013
- 2013-09-06 CN CN201310399592.4A patent/CN103417952B/en active Active
Non-Patent Citations (1)
| Title |
|---|
| 类风湿关节炎从中医三痹治疗探讨;朱益忠;《浙江中医药大学学报》;20071130;第31卷(第6期);第720-721页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103417952A (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104352991A (en) | Traditional Chinese medicine preparation for treating gout and preparation method thereof | |
| CN103735791B (en) | A kind of Chinese medicine composition and preparation method thereof for the treatment of lumbar vertebra, bone diseases | |
| CN102091311B (en) | Traditional Chinese medicinal composition for treating rheumatoid arthritis and preparation method thereof | |
| CN103735927B (en) | A kind of Chinese medicine composition for the treatment of acute stage of gout and preparation method thereof | |
| CN104784589A (en) | Medicinal composition for treating ankylosing spondylitis and preparation method of medicinal composition | |
| CN101112533B (en) | A Chinese medicinal composition for treating and preventing gout, and its preparation method | |
| CN105709074A (en) | Medicine for treating rheumatic arthritis and hyperostosis and preparation method | |
| CN105727117A (en) | Medicine for treating prostatic hyperplasia and preparation method thereof | |
| CN101708292B (en) | Chinese medicament for treating rheumatic and rheumatoid diseases | |
| CN1248727C (en) | Insensitive impediment capsule and its manufacturing method | |
| CN103417952B (en) | Oral medicine composition for treating rheumatoid arthritis | |
| CN104383050B (en) | A kind of medicine of combination of inner and outside treatment rheumatic arthritis and preparation method | |
| CN103272064A (en) | Traditional Chinese medicine for treating rheumatoid arthritis and preparation method of traditional Chinese medicine | |
| CN106511905A (en) | Traditional Chinese medicine preparation used for curing cervical spondylosis and preparation method thereof | |
| CN106237181A (en) | A kind of Chinese medicine composition treating rheumatoid arthritis and capsule thereof and preparation method | |
| CN106039131A (en) | Traditional Chinese medicinal compound preparation for treating IgA nephrosis with hyperuricemia, and preparation method and use thereof | |
| CN102357228A (en) | Traditional Chinese medicine combination for treating liver diseases | |
| CN105561272A (en) | Traditional Chinese medicine preparation for relieving Reynolds disease and preparation method thereof | |
| CN102406792B (en) | Pharmaceutical composition for rapidly promoting healing of bone fracture | |
| CN104857394A (en) | Traditional Chinese medicine combination preparation for treating gout and preparation method of traditional Chinese medicine | |
| CN105106499A (en) | Traditional Chinese medicinal composition used after surgical shunting of stenosing cholangitis | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN105169342A (en) | Traditional Chinese medicine composition for treating eczema and preparation method thereof | |
| CN103977267A (en) | Traditional Chinese medicine for treating lupus erythematosus | |
| CN104857349A (en) | Pure traditional Chinese medicine preparation for treating stroke and preparation method of pure traditional Chinese medicine preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Nie Qiling Inventor after: Ma Huali Inventor before: Wang Yuling |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG YULING TO: NIE QILING MA HUALI |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170503 Address after: 226200 Jiangsu province Nantong Jiulong Zhen Yuan Dong Cun highstar Chemical Co. Ltd. in Patentee after: Qidong Su Xing carbon dioxide Co., Ltd. Address before: 276017 Linyi hi tech Industrial Development Zone, innovation building, building 2, Di Di, Shandong science and Technology Information Service Center Patentee before: Yang Xianhua |
|
| TR01 | Transfer of patent right |